Product Description
Wyeth was developing the small molecule plasminogen activator inhibitor-1 (PAI-1) antagonist aleplasinin for the treatment of Alzheimer's disease in the US. PAZ-417 inhibits PAI-I (Plasminogen activator inhibitor-1), thereby increasing the activation of plasminogen to form plasmin. (Sourced from: https://drugs.ncats.io/drug/LL56J87F3X)
Mechanisms of Action: PLA Activator
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: N/A
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Pfizer
Company Location: Eastern America
Company CEO: Albert Bourla
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 1: Alzheimer Disease|Healthy Volunteers
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT00366288 |
3186A1-100 | N/A |
Completed |
Alzheimer Disease |
2008-03-01 |
2019-03-21 |
Treatments |
|
NCT00663065 |
3186A1-1102 | P1 |
Terminated |
Healthy Volunteers |
2008-12-01 |
2019-03-18 |
Treatments |
|
NCT00739037 |
3186A1-1103 | P1 |
Terminated |
Alzheimer Disease |
2008-12-01 |
2019-03-18 |
Treatments |
|
NCT00684710 |
3186A1-101 | P1 |
Completed |
Alzheimer Disease |
2008-08-01 |
2019-03-18 |
Recent News Events
Date |
Type |
Title |
|---|